<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-145107" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pheochromocytoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Puneet K.</given-names>
          </name>
          <aff>University of Louisville</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marwaha</surname>
            <given-names>Bharat</given-names>
          </name>
          <aff>Government Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Puneet Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bharat Marwaha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>11</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-145107.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>A pheochromocytoma is a rare tumor&#x000a0;originating&#x000a0;from chromaffin cells in the adrenal medulla. Pheochromocytomas clinical manifestations stem from the overproduction of catecholamines&#x02014;a group of hormones and neurotransmitters essential for maintaining homeostasis and regulating the&#x000a0;body's response to stress.&#x000a0;These chemicals are produced primarily by the adrenal glands and nerve tissue,&#x000a0;including the brain.&#x000a0;The primary catecholamines are dopamine, norepinephrine, and epinephrine. Pheochromocytomas can be benign or malignant and are often associated with&#x000a0;familial syndromes such as neurofibromatosis type 1, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease.</p>
        <p>Sporadic pheochromocytomas are frequently overlooked causes of secondary hypertension, although they may also be detected incidentally during imaging for other conditions. Clinical manifestations arise mainly from catecholamine excess, and about half of these tumors primarily produce epinephrine, while others mainly secrete norepinephrine. Diagnosis is confirmed through biochemical tests measuring the excess production of metanephrines and catecholamines and imaging studies to identify the tumor's location. Surgical resection is the definitive treatment. Preoperative management typically involves &#x003b1;- and &#x003b2;-adrenergic blockade to mitigate potential complications.&#x000a0;This article reviews the evaluation and management of pheochromocytomas and emphasizes the critical role of the interprofessional healthcare team in diagnosing and treating affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at risk for pheochromocytomas, particularly those with a family history of related syndromes such as neurofibromatosis type 1 or von Hippel-Lindau disease.</p></list-item><list-item><p>Assess the severity of symptoms and potential complications related to catecholamine excess prior to surgical intervention.</p></list-item><list-item><p>Apply preoperative management protocols, including alpha- and beta-adrenergic blockade, to mitigate the risk of hypertensive crises.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team to ensure comprehensive follow-up care throughout the diagnostic and treatment processes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145107&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145107">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-145107.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A pheochromocytoma is a rare tumor originating from chromaffin cells in the adrenal medulla. Pheotochromocytomas&#x000a0;clinical manifestations result from excessive catecholamine secretion. Catecholamines are a group of hormones and neurotransmitters crucial&#x000a0;for regulating homeostasis and managing the body's response to stress. These chemicals are primarily produced by the adrenal gland and nerve tissue, including the brain. The principal&#x000a0;catecholamines are dopamine, norepinephrine, and epinephrine.</p>
        <p>Pheochromocytoma is a neoplasm that can be either benign or malignant and is often associated with familial syndromes such as neurofibromatosis type 1 (NF1), multiple endocrine neoplasia type 2 (MEN2), and von Hippel-Lindau (VHL) disease. In addition, sporadic cases are also significant, as they are among the most commonly overlooked causes of secondary hypertension (see <bold>Image.</bold> Gross Specimen of a Giant Pheochromocytoma).</p>
        <p>The clinical manifestations of these tumors are primarily due to the excessive secretion of catecholamines. Tumors that arise from extra-adrenal chromaffin cells are known as paragangliomas, and both types are often studied together as neuroendocrine tumors due to their similar characteristics. Pheochromocytomas account for 80% to 85% of these tumors, while sympathetic paragangliomas account for 15% to 20%.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref><xref ref-type="bibr" rid="article-145107.r2">[2]</xref>&#x000a0;Although most pheochromocytomas are benign, a small percentage can be malignant.<xref ref-type="bibr" rid="article-145107.r3">[3]</xref>&#x000a0;</p>
        <p>In the past, pheochromocytomas were primarily identified during evaluations for secondary hypertension. However, they are now increasingly found as incidental findings on abdominal imaging conducted for other conditions or through surveillance screening in individuals with known genetic disorders.<xref ref-type="bibr" rid="article-145107.r2">[2]</xref></p>
        <p>Pheochromocytomas generally exhibit a predominant type of catecholamine production. Around half primarily secrete epinephrine with varying levels of norepinephrine. Others, including sympathetic paragangliomas, mainly produce norepinephrine with dopamine as a by-product.<xref ref-type="bibr" rid="article-145107.r2">[2]</xref>&#x000a0;Dopamine production is considered an independent predictor of malignancy, likely due to its role in promoting angiogenesis.<xref ref-type="bibr" rid="article-145107.r4">[4]</xref></p>
      </sec>
      <sec id="article-145107.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Pheochromocytomas can arise sporadically or have a familial origin. Recent studies suggest that up to 35% of cases may be linked to germline mutations.<xref ref-type="bibr" rid="article-145107.r5">[5]</xref> Familial syndromes known to be associated with pheochromocytomas include VHL disease, MEN2, and NF1.</p>
        <p>Over half of pheochromocytomas occur sporadically, without any known connection to inherited disorders, and their underlying cause often remains unknown. However, individuals with a family history of pheochromocytoma or paraganglioma have an increased risk of developing the condition.</p>
        <p>Pheochromocytomas can develop due to the factors mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Genetics: Inherited mutations in various genes, including&#x000a0;<italic toggle="yes">RET</italic>,&#x000a0;<italic toggle="yes">VHL</italic>, or&#x000a0;<italic toggle="yes">NF1,</italic>&#x000a0;can lead to pheochromocytoma.</p>
          </list-item>
          <list-item>
            <p>Sporadic:&#x000a0;Approximately two-thirds of pheochromocytomas occur spontaneously, without a known family history. However, genetic factors may still be involved in these instances.</p>
          </list-item>
          <list-item>
            <p>Additional factors: Other contributors to pheochromocytoma (or its discovery) include intense physical activity, trauma, emotional stress, childbirth, anesthesia, and surgery.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145107.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Similar to&#x000a0;many secondary causes of hypertension, pheochromocytomas are often underdiagnosed. An autopsy study revealed undiagnosed pheochromocytomas in 0.05% of individuals.<xref ref-type="bibr" rid="article-145107.r6">[6]</xref>&#x000a0;In a single-center study of 4180 patients in Brooklyn, pheochromocytomas were identified in 0.2% of those with hypertension, resulting in an average annual incidence rate of 0.5 cases per 100,000 person-years.<xref ref-type="bibr" rid="article-145107.r7">[7]</xref></p>
      </sec>
      <sec id="article-145107.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Catecholamines are produced in chromaffin cells, beginning with the rate-limiting conversion of tyrosine to dihydroxyphenylalanine (DOPA) by tyrosine hydroxylase. DOPA is then converted into dopamine by the action of DOPA decarboxylase, which is further converted into norepinephrine by dopamine &#x003b2;-hydroxylase. Finally, norepinephrine is methylated by phenylethanolamine-<italic toggle="yes">N</italic>-methyltransferase to produce epinephrine. These catecholamines are stored in vesicles and released into the blood circulation, with cardiac manifestations mediated through adrenoreceptors.<xref ref-type="bibr" rid="article-145107.r8">[8]</xref></p>
        <p>Pheochromocytomas release catecholamines in different patterns, classified as paroxysmal, continuous, or mixed. Norepinephrine is typically released continuously, leading to persistent hypertension, while epinephrine is released in a paroxysmal manner, which can cause tachyarrhythmias.<xref ref-type="bibr" rid="article-145107.r9">[9]</xref><xref ref-type="bibr" rid="article-145107.r10">[10]</xref>&#x000a0;The alpha-1 and alpha-2 (&#x003b1;-1 and &#x003b1;-2) adrenoreceptors&#x000a0;and beta-1 and beta-2 (&#x003b2;-1 and &#x003b2;-2) adrenoreceptors bind epinephrine and norepinephrine with varying affinities. Epinephrine binds to &#x003b2;-1 and &#x003b2;-2 receptors with similar affinity, while norepinephrine is approximately 10-fold more selective for the &#x003b2;-1 receptor.<xref ref-type="bibr" rid="article-145107.r11">[11]</xref>&#x000a0;The &#x003b1;-1 receptors exhibit greater selectivity for norepinephrine than for epinephrine,<xref ref-type="bibr" rid="article-145107.r12">[12]</xref>&#x000a0;and dopamine has an affinity for &#x003b1;-2 receptors. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17240">Adrenergic Drugs</ext-link>," for more information. Glucocorticoids and thyroid hormones can influence these adrenoceptors by either increasing their numbers or affecting their affinity.<xref ref-type="bibr" rid="article-145107.r13">[13]</xref><xref ref-type="bibr" rid="article-145107.r14">[14]</xref><xref ref-type="bibr" rid="article-145107.r15">[15]</xref></p>
        <p>The heart contains &#x003b2;-1 adrenoceptors, and their stimulation activates adenylate cyclase via the guanine triphosphate protein-coupled receptor. This activation converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The&#x000a0;increase in cAMP activates hyperpolarization-activated cyclic nucleotide-gated channels and protein kinase A. This signaling cascade may increase ionotropy in SA nodal cells and dromotropy in AV nodal cells.<xref ref-type="bibr" rid="article-145107.r16">[16]</xref></p>
        <p>&#x003b2;-2 adrenoceptors are found in peripheral blood vessels and can induce vasodilation when activated by epinephrine and norepinephrine. In contrast, &#x003b1;-adrenoceptors located in vascular smooth muscle cells can cause hypertension through vasoconstriction when activated by norepinephrine and epinephrine. Additionally, &#x003b1;-2 adrenoceptors at synaptic nerve terminals inhibit the release of norepinephrine.</p>
      </sec>
      <sec id="article-145107.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathological evaluation of pheochromocytomas typically reveals a zellballen pattern characterized by nests of chromaffin cells. These cells show strong positivity for chromogranin, synaptophysin, CD56, and focal positivity for S100.<xref ref-type="bibr" rid="article-145107.r17">[17]</xref><xref ref-type="bibr" rid="article-145107.r18">[18]</xref> The presence of chromaffin cells in the extra-adrenal tissue is the only pathognomonic characteristic of the malignant form of the entity.<xref ref-type="bibr" rid="article-145107.r17">[17]</xref></p>
      </sec>
      <sec id="article-145107.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In pheochromocytoma, episodes of hypertension are often paroxysmal and have been associated with symptoms such as headaches, tachycardia, and sweating. However, patients may also present with sustained resistant hypertension. The presence of hypertension that is resistant to multiple antihypertensive therapies should raise suspicion for pheochromocytoma.&#x000a0;Severe hypertension episodes may be triggered by dopamine receptor antagonists, non-selective &#x003b2;-blockers, tricyclic antidepressants, corticosteroids, sympathomimetics, and neuromuscular agents. Symptoms can also arise during surgery or anesthesia induction.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref>&#x000a0;</p>
        <p>The condition is often diagnosed through screening tests after establishing a familial diagnosis in familial syndromes associated with pheochromocytoma. Many of these patients do not present with hypertension at the time of diagnosis. Giant lesions may paradoxically present solely as abdominal masses with minimal characteristic symptoms of pheochromocytoma. This occurs due to tumoral necrosis, a higher proportion of interstitial tissue relative to chromaffin cells, and encapsulation by connective tissues (see <bold>Image.</bold>&#x000a0;A Giant&#x000a0;Pheochromocytoma).<xref ref-type="bibr" rid="article-145107.r17">[17]</xref>&#x000a0;</p>
        <p>
<bold>Familial Pheochromocytomas</bold>
</p>
        <p>Pheochromocytomas are associated with several hereditary syndromes, including VHL disease, MEN2, and NF1. All these syndromes follow an autosomal dominant pattern of inheritance.</p>
        <p><bold>von Hippel-Lindau disease:</bold> The phenotype of VHL disease typically includes hemangioblastomas of the brain and spine, retinal angiomas, clear cell renal cell carcinomas, pheochromocytomas, paragangliomas, pancreatic neuroendocrine tumors, endolymphatic sac tumors of the middle ear, and cystadenomas of the pancreas, epididymis, and broad ligament. The condition is usually caused by mutations in the <italic toggle="yes">VHL</italic> tumor suppressor gene.<xref ref-type="bibr" rid="article-145107.r19">[19]</xref>&#x000a0;Patients with VHL type&#x000a0;1 have a lower risk of developing pheochromocytomas compared to those with VHL type 2.<xref ref-type="bibr" rid="article-145107.r20">[20]</xref>&#x000a0;Additionally, individuals with VHL disease tend to exhibit higher levels of the norepinephrine metabolite normetanephrine than those with MEN2.<xref ref-type="bibr" rid="article-145107.r21">[21]</xref>&#x000a0;</p>
        <p><bold>Multiple endocrine neoplasia type 2:</bold> The typical phenotype of MEN2 includes medullary thyroid cancer, pheochromocytomas, primary hyperparathyroidism, mucocutaneous neuromas, skeletal deformities, intestinal ganglioneuromas, and cutaneous lichen amyloidosis. This syndrome is caused by mutations in the <italic toggle="yes">RET</italic> proto-oncogene and is inherited in an autosomal dominant manner.<xref ref-type="bibr" rid="article-145107.r22">[22]</xref>&#x000a0;Patients with MEN2 often exhibit elevated levels of metanephrines, particularly the epinephrine metabolite, and tend to be more symptomatic, with a higher incidence of hypertension compared to those with VHL disease.<xref ref-type="bibr" rid="article-145107.r21">[21]</xref></p>
        <p><bold>Neurofibromatosis type 1:</bold> NF1 is caused by mutations in the <italic toggle="yes">NF1</italic> tumor suppressor gene and is inherited in an autosomal dominant manner.<xref ref-type="bibr" rid="article-145107.r23">[23]</xref>&#x000a0;Diagnosis is typically made clinically, with characteristic features including caf&#x000e9;-au-lait macules, axillary freckling, Lisch nodules, optic gliomas, osseous lesions, and neurofibromas.<xref ref-type="bibr" rid="article-145107.r24">[24]</xref>&#x000a0;Pheochromocytomas&#x000a0;occur in a small proportion of NF1 patients, with studies reporting their presence in 0.1% to 5.7% of patients with NF1.<xref ref-type="bibr" rid="article-145107.r25">[25]</xref>&#x000a0;</p>
        <p>
<bold>Subclinical Presentation</bold>
</p>
        <p>Pheochromocytomas can present with varied clinical presentations depending on their secretory patterns. Dopamine-secreting tumors and those with minimal hormone secretion may lead to subclinical or mild disease. Dopamine-secreting tumors often simultaneously release norepinephrine, and the counteractive effects of these hormones on blood vessels can reduce the development of overt clinical signs and symptoms.<xref ref-type="bibr" rid="article-145107.r26">[26]</xref></p>
        <p>The recent increase in genetic screening of family members has led to increased detection of patients with subclinical disease. Tumors with succinate dehydrogenase complex iron-sulfur subunit B (<italic toggle="yes">SDHB</italic>) mutations often exhibit an undifferentiated catecholamine biosynthetic&#x000a0;phenotype with low catecholamine concentrations. As a result, these tumors can present subclinically until they grow large enough to produce noticeable signs and symptoms.<xref ref-type="bibr" rid="article-145107.r27">[27]</xref>&#x000a0;</p>
        <p>Catecholamine secretory patterns can produce varying clinical presentations. Epinephrine-secreting tumors often cause paroxysmal hypertensive crises but may also have a silent course. In contrast, norepinephrine-secreting tumors typically result in essential hypertension. Chronically elevated levels of norepinephrine can lead to downregulation of adrenoreceptors, which may contribute to a milder clinical presentation.<xref ref-type="bibr" rid="article-145107.r28">[28]</xref><xref ref-type="bibr" rid="article-145107.r29">[29]</xref></p>
        <p>Patients with subclinical disease are also at significant cardiovascular risk, with case reports describing sudden hypertensive crises leading to sudden death.<xref ref-type="bibr" rid="article-145107.r30">[30]</xref><xref ref-type="bibr" rid="article-145107.r31">[31]</xref>&#x000a0;Mechanical factors&#x000a0;such as abdominal palpation, sexual intercourse, coughing, sneezing, defecation, pain, extreme emotions, and exposure to cold can trigger hypertensive crises in otherwise asymptomatic catecholamine-secreting tumors. Annual screening with plasma or urinary metanephrines is recommended for genetic carriers to facilitate early detection of disease.</p>
        <p>Another important aspect of subclinical presentation involves incidentalomas discovered through imaging, most commonly on computed tomography (CT). These findings are prevalent in 6% of autopsy studies and 4% of CT scans.<xref ref-type="bibr" rid="article-145107.r32">[32]</xref><xref ref-type="bibr" rid="article-145107.r33">[33]</xref>&#x000a0;The adrenal glands develop nodules with advancing age and are reported to have a 7% prevalence in individuals aged 70 or older. More than 4% were reported to be pheochromocytomas in a large series of incidentalomas.<xref ref-type="bibr" rid="article-145107.r34">[34]</xref>&#x000a0;Screening with plasma or urinary metanephrines is recommended surgery involving adrenal incidentalomas to ensure appropriate management.</p>
        <p>In summary, examination findings may include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Subcutaneous neurofibromas</p>
          </list-item>
          <list-item>
            <p>Caf&#x000e9;-au-lait macules</p>
          </list-item>
          <list-item>
            <p>Thyroid mass</p>
          </list-item>
          <list-item>
            <p>Axillary freckling</p>
          </list-item>
          <list-item>
            <p>Iridic Lisch nodules</p>
          </list-item>
          <list-item>
            <p>Retinal angiomas</p>
          </list-item>
          <list-item>
            <p>Abdominal mass</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145107.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>In the appropriate clinical scenario, diagnosis of pheochromocytoma can be established by biochemical confirmation of hypersecretion of metanephrines and catecholamines. According to the latest Endocrine Society Clinical Practice Guidelines, the initial biochemical evaluation should include either plasma-fractionated metanephrines or urinary-fractionated metanephrines.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref></p>
        <p>Catecholamines are rapidly inactivated by the enzyme catechol-O-methyltransferase, producing metanephrine and normetanephrine, which are subsequently conjugated with sulfate. These metabolites have a longer half-life and are excreted in the urine, making them more suitable for measurement than catecholamines. Elevated plasma metanephrines are considered more specific for diagnosing pheochromocytoma than urinary metanephrines, with higher levels correlating with larger tumor sizes. The European Society Clinical Practice Guidelines recommend liquid chromatography with mass spectrometry or electrochemical detection for optimal accuracy. Reported sensitivities for urinary metanephrines range from 86% to 97%, with specificities between 69% and 95%.<xref ref-type="bibr" rid="article-145107.r35">[35]</xref></p>
        <p>
<bold>Key Considerations in Biochemical Testing for Pheochromocytoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Although pheochromocytoma is a rare condition that&#x000a0;causes catecholamine excess, the low pretest probability of the disease means that test results must be interpreted with caution.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Plasma-free metanephrines are the most reliable test for confirming or ruling out pheochromocytoma.</p>
          </list-item>
          <list-item>
            <p>Given the frequency of testing and the low incidence of true pheochromocytoma, false positives significantly outnumber true positives&#x02014;a pattern also observed with paraganglioma.<xref ref-type="bibr" rid="article-145107.r36">[36]</xref><xref ref-type="bibr" rid="article-145107.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Additional laboratory findings may include hyperglycemia, hypercalcemia, and erythrocytosis.</p>
          </list-item>
        </list>
        <p>Several studies have shown that plasma metanephrine concentrations tend to be higher when measured in the seated position compared to the supine position, leading to reduced specificity and an increase in false positive results.<xref ref-type="bibr" rid="article-145107.r38">[38]</xref><xref ref-type="bibr" rid="article-145107.r39">[39]</xref><xref ref-type="bibr" rid="article-145107.r40">[40]</xref>&#x000a0;Guidelines recommend drawing blood with the patient in the supine position after they have been fully recumbent for at least 30 minutes before sampling.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref>&#x000a0;When logistical constraints make this unfeasible, positive results from seated samples should be confirmed with repeat testing in the supine position. Reference intervals specific to the patient&#x02019;s position during sampling must be applied.</p>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>Following biochemical confirmation, the next suggested evaluation step is to locate the tumor using imaging studies. Per guidelines, a CT of the abdomen and pelvis is the recommended initial imaging test to locate the tumor. Current guidelines suggest an initial CT scan of the abdomen and pelvis. Pheochromocytomas on CT typically present as low-density lesions relative to soft tissue. However, lesions larger than 3 cm can display variable appearances, potentially mimicking other adrenal tumors.</p>
        <p>Magnetic resonance imaging (MRI) serves as a viable alternative, especially when avoiding radiation or contrast is preferred, although it offers lower spatial resolution than CT.&#x000a0;Pheochromocytomas typically appear as hyperintense lesions on T2-weighted imaging. For metastatic disease, fluorodeoxyglucose F18 (FDG) positron emission tomography (PET) is recommended. A&#x000a0;<sup>123</sup>I-metaiodobenzylguanidine (MIBG) scan is an alternate option, particularly when radiotherapy with&#x000a0;<sup>123</sup>I-MIBG is being considered.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref></p>
        <p>
<bold>Genetic Testing</bold>
</p>
        <p>Given that up to 35% of pheochromocytoma cases may be related to germline disease-causing mutations, genetic testing should be considered for all patients diagnosed with pheochromocytoma.<xref ref-type="bibr" rid="article-145107.r5">[5]</xref> Bilateral tumors and those that present at younger ages are more frequently associated with hereditary syndromes.</p>
        <p>Once pheochromocytoma is diagnosed, a thorough clinical evaluation and family history can help identify characteristic symptoms and signs of hereditary syndromes associated with the condition. In such cases, targeted genetic testing for <italic toggle="yes">VHL</italic>, <italic toggle="yes">MEN2</italic>, and <italic toggle="yes">NF1</italic> syndromes is recommended. After identifying a pathogenic mutation, genetic screening for first-degree relatives should also be considered.</p>
        <p>Typical sporadic cases of pheochromocytoma are unilateral and associated with an adverse family history, as well as an absence of syndromic symptoms and signs. Individuals with sporadic cases should be clinically monitored for the development of characteristic signs of hereditary syndromes. Genetic testing should be considered in sporadic cases where clinical suspicion arises. A study from Germany found that characteristic mutations were detected in 24% of patients with apparently sporadic pheochromocytoma.<xref ref-type="bibr" rid="article-145107.r41">[41]</xref></p>
        <p>Several genes associated with the development of pheochromocytomas have been identified and categorized into 3 clusters based on the mechanism of tumorigenesis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pseudohypoxia pathway (cluster 1): This cluster has been associated with mutations in the&#x000a0;<italic toggle="yes">EGLN1</italic>,&#x000a0;<italic toggle="yes">EGLN2</italic>,&#x000a0;<italic toggle="yes">DLST</italic>,&#x000a0;<italic toggle="yes">FH</italic>,&#x000a0;<italic toggle="yes">IDH3B</italic>,&#x000a0;<italic toggle="yes">MDH2</italic>,&#x000a0;<italic toggle="yes">SDHA</italic>,&#x000a0;<italic toggle="yes">SDHAF2</italic>,&#x000a0;<italic toggle="yes">SDHB</italic>,&#x000a0;<italic toggle="yes">SDHC</italic>,&#x000a0;<italic toggle="yes">SDHD</italic>, <italic toggle="yes">VHL</italic>,&#x000a0; <italic toggle="yes">EPAS1</italic>,&#x000a0;<italic toggle="yes">IDH1</italic>, and&#x000a0;<italic toggle="yes">IDH2</italic> genes.</p>
          </list-item>
          <list-item>
            <p>Kinase-signaling pathway (cluster 2): This has been associated with mutations in the&#x000a0;<italic toggle="yes">NF1</italic>,&#x000a0;<italic toggle="yes">MAX</italic>,&#x000a0;<italic toggle="yes">MERTK</italic>,&#x000a0;<italic toggle="yes">MET</italic>,&#x000a0;<italic toggle="yes">MYCN</italic>,&#x000a0;<italic toggle="yes">RET</italic>, and&#x000a0;<italic toggle="yes">TMEM127</italic> genes.</p>
          </list-item>
          <list-item>
            <p>Somatic cluster (cluster 3): This has been associated with alterations in the <italic toggle="yes">Wnt</italic> signaling pathway.<xref ref-type="bibr" rid="article-145107.r42">[42]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145107.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The definitive treatment for pheochromocytoma is surgical resection, with preoperative &#x003b1;- and &#x003b2;-adrenergic blockade being crucial.<xref ref-type="bibr" rid="article-145107.r43">[43]</xref></p>
        <p>
<bold>Unilateral Pheochromocytoma</bold>
</p>
        <p>Most sporadic tumors are unilateral. According to the Endocrine Society Clinical Practice Guidelines, adrenalectomy via a minimally invasive approach is the preferred treatment for most unilateral adrenal pheochromocytomas. Open adrenalectomy may be considered for larger tumors or in cases where the tumor is considered invasive.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref></p>
        <p>
<bold>Bilateral Pheochromocytoma&#x000a0;</bold>
</p>
        <p>Bilateral neoplasms are most commonly associated with hereditary cases, particularly MEN2 and VHL disease.<xref ref-type="bibr" rid="article-145107.r44">[44]</xref>&#x000a0;In these cases, bilateral total adrenalectomy necessitates lifelong steroid replacement, which can lead to long-term adverse effects.<xref ref-type="bibr" rid="article-145107.r45">[45]</xref>&#x000a0;Alternatively, bilateral partial or cortical-sparing adrenalectomy can be performed via any surgical approach. This option has demonstrated comparable survival rates despite tumor recurrence and better preservation of adrenocortical function, resulting in a reduced need for lifelong glucocorticoid replacement therapy.<xref ref-type="bibr" rid="article-145107.r45">[45]</xref><xref ref-type="bibr" rid="article-145107.r46">[46]</xref></p>
        <p>
<bold>Preoperative Preparation</bold>
</p>
        <p>No randomized studies exist to guide medical optimization approaches before surgery. However, it is well-recognized that initiating medical therapy with &#x003b1;- and &#x003b2;-blockade in the preoperative period can significantly reduce the risk of uncontrolled hypertension, hypertensive crises, tachycardia, and volume expansion during the perioperative period.<xref ref-type="bibr" rid="article-145107.r43">[43]</xref></p>
        <p>According to the Endocrine Society Clinical Practice Guidelines, the first-line drugs for preoperative preparation are &#x003b1;-adrenergic receptor blockers.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref> A typical regimen involves initiating phenoxybenzamine 7 to 14 days before surgery, starting at a dosage of 10 mg orally twice daily and carefully titrating up to a maximum of 1 mg/kg/d. Doxazosin, an &#x003b1;-1 selective agent, is an acceptable alternative due to its favorable adverse effect profile.</p>
        <p>At least 3 to 4 days after starting &#x003b1;-blockade, &#x003b2;-blockade with propranolol, atenolol, or metoprolol should be initiated to manage tachycardia. These agents should not be started without prior &#x003b1;-blockade, as doing so may precipitate a hypertensive crisis due to unopposed &#x003b1;-receptor stimulation.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref>&#x000a0;Calcium&#x000a0;channel blockers, such as amlodipine and nifedipine, can serve as alternative or add-on agents to effectively control hypertension in the preoperative period.<xref ref-type="bibr" rid="article-145107.r47">[47]</xref></p>
        <p>Volume contraction related to catecholamine excess in patients with pheochromocytoma can be managed by starting a high-sodium diet a few days after initiating &#x003b1;-blockade. This approach can also help reduce the risk of hypotension following surgery.<xref ref-type="bibr" rid="article-145107.r9">[9]</xref></p>
        <p>
<bold>Perioperative Concerns</bold>
</p>
        <p>The key elements of perioperative management are 4-fold. First, prevention of catecholamine surge is achieved through minimal handling of the lesion and avoiding spillage of tumor contents, particularly in cystic lesions. Second, early intraoperative control of the adrenal vein is crucial. Lastly, effective management of sudden hypotension, characterized by a decrease in peripheral vascular resistance following surgical removal of the lesion, is essential.<xref ref-type="bibr" rid="article-145107.r17">[17]</xref></p>
        <p>
<bold>Nonsurgical Management </bold>
</p>
        <p>Nonsurgical management of pheochromocytomas may involve radiotherapy, chemotherapy, and palliative care. According to the 2017 National Comprehensive Cancer Network guidelines, treatment options for malignant paraganglioma and pheochromocytoma include cytoreductive surgery when feasible, systemic chemotherapy (commonly consisting of cyclophosphamide, vincristine, and dacarbazine or temozolomide), or <sup>131</sup>I-MIBG.</p>
        <p>Percutaneous ablation has emerged as a minimally invasive local treatment option for pheochromocytoma.<xref ref-type="bibr" rid="article-145107.r48">[48]</xref><xref ref-type="bibr" rid="article-145107.r49">[49]</xref>&#x000a0;Small retrospective studies have indicated that external beam radiation therapy may serve as a useful local treatment modality for some patients with advanced or unresectable malignant pheochromocytoma.<xref ref-type="bibr" rid="article-145107.r50">[50]</xref><xref ref-type="bibr" rid="article-145107.r51">[51]</xref></p>
        <p>
<bold>Embolization in Pheochromocytoma Treatment</bold>
</p>
        <p>Embolization involves blocking the artery supplying blood to a tumor. Spontaneous remission of hypercatecholaminergic crises associated with pheochromocytomas, particularly those with extensive necrosis, has been linked to the exhaustion of catecholamine secretion before surgical tumor resection.<xref ref-type="bibr" rid="article-145107.r52">[52]</xref>&#x000a0;In situations where emergent surgery and medical control using &#x003b1;-1 blockade pose a high risk, treatment options may include mechanical circulatory support with a cardiopulmonary device or intra-aortic balloon pump or the removal of catecholamines through continuous hemodiafiltration.<xref ref-type="bibr" rid="article-145107.r53">[53]</xref>&#x000a0;</p>
        <p>Alternatively, emergent transcatheter arterial embolization is being considered a safer modality for the urgent treatment of critical blood pressure fluctuations associated with pheochromocytoma-related hypercatecholaminergic crises. This approach can quickly stabilize blood pressure, allowing for future elective surgical tumor resection in a more controlled setting.<xref ref-type="bibr" rid="article-145107.r54">[54]</xref></p>
        <p>
<bold>Palliative Treatment in Advanced Metastatic Pheochromocytoma</bold>
</p>
        <p>The palliative treatment approach for advanced metastatic pheochromocytoma focuses on relieving symptoms and improving quality of life. This may involve surgical intervention to remove as much of the tumor as possible or radiation therapy to target areas affected by the cancer. Additionally, medications such as &#x003b1;- and &#x003b2;-blockers can be used to manage disease-related symptoms effectively.</p>
      </sec>
      <sec id="article-145107.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of pheochromocytoma includes various causes of primary and secondary hypertension, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperthyroidism</p>
          </list-item>
          <list-item>
            <p>Anxiety disorder</p>
          </list-item>
          <list-item>
            <p>Renal artery stenosis</p>
          </list-item>
          <list-item>
            <p>Hyperaldosteronism</p>
          </list-item>
          <list-item>
            <p>Migraine headache</p>
          </list-item>
          <list-item>
            <p>Preeclampsia</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Postural tachycardia syndrome</p>
          </list-item>
          <list-item>
            <p>Drug-induced hypertension</p>
          </list-item>
          <list-item>
            <p>Cushing syndrome</p>
          </list-item>
          <list-item>
            <p>Carcinoid syndrome</p>
          </list-item>
          <list-item>
            <p>Acrodynia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145107.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>
<bold>Metastatic Pheochromocytomas</bold>
</p>
        <p>Approximately 10% of pheochromocytomas are classified as malignant, characterized by the presence of metastasis. Currently, no definitive histological or biochemical features exist that can reliably distinguish malignant pheochromocytomas from benign ones, except for the identification of chromaffin cells in extra-adrenal tissue.<xref ref-type="bibr" rid="article-145107.r17">[17]</xref><xref ref-type="bibr" rid="article-145107.r55">[55]</xref>&#x000a0;The Pheochromocytoma of the Adrenal gland Scaled Score (PASS) has been applied to differentiate benign lesions from their malignant counterparts.<xref ref-type="bibr" rid="article-145107.r17">[17]</xref><xref ref-type="bibr" rid="article-145107.r18">[18]</xref></p>
        <p>
<bold>Surgery</bold>
</p>
        <p>Resection of both primary and metastatic disease should be considered when technically feasible, although it is unlikely to result in a complete cure. The surgical approach must be individualized based on the location of the metastases and may involve either open or minimally invasive techniques. Larger tumors are typically treated using an open approach, as this method is associated with a lower risk of tumor rupture and may facilitate the simultaneous removal of metastases.<xref ref-type="bibr" rid="article-145107.r55">[55]</xref><xref ref-type="bibr" rid="article-145107.r56">[56]</xref></p>
        <p>Debulking both primary and metastatic lesions may alleviate symptoms associated with catecholamine surges.<xref ref-type="bibr" rid="article-145107.r55">[55]</xref><xref ref-type="bibr" rid="article-145107.r56">[56]</xref>&#x000a0;However, the reported 5-year survival rate is only 50%.<xref ref-type="bibr" rid="article-145107.r17">[17]</xref></p>
      </sec>
      <sec id="article-145107.s12" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>A phase II trial of temozolomide and olaparib is currently underway. This trial aims to assess whether combining olaparib (a PARP inhibitor) with temozolomide (a chemotherapeutic agent) is more effective for treating metastatic or unresectable neuroendocrine tumors compared to using temozolomide alone. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT04394858">https://clinicaltrials.gov/study/NCT04394858</ext-link>)</p>
        <p>The mechanism of olaparib is the inhibition of PARP proteins, which are involved in the repair of DNA damage in tumor cells. By blocking this repair mechanism, olaparib may hinder the ability of tumor cells to recover from DNA damage, potentially leading to their death or slowed growth. Temozolomide is a chemotherapy drug that kills tumor cells or prevents their division and spread by inducing DNA damage.</p>
        <p>The trial aims to determine whether the synergistic effect of combining these two drugs can enhance treatment effectiveness for neuroendocrine cancers that are challenging to treat with existing methods. Other phase II trials of the vascular endothelial growth factor (VEGF) inhibitors lenvatinib and dovitinib are ongoing for patients with pheochromocytoma or paraganglioma.</p>
      </sec>
      <sec id="article-145107.s13" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>The treatment for pheochromocytoma or paraganglioma that has metastasized to nearby organs or lymph nodes typically involves surgical resection to completely remove the tumor. This may include excising not only the primary tumor but also affected adjacent organs, such as the kidney or liver, as well as sections of major blood vessels and lymph nodes that have been invaded by cancer.</p>
      </sec>
      <sec id="article-145107.s14" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Phenoxybenzamine is a medication used to manage and treat paroxysmal hypertension and sweating associated with pheochromocytoma.</p>
        <p>
<bold>Adverse&#x000a0;Effects</bold>
</p>
        <p>Adverse effects of phenoxybenzamine include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibited ejaculation</p>
          </list-item>
          <list-item>
            <p>Orthostatic hypotension</p>
          </list-item>
          <list-item>
            <p>Tachycardia (reflex tachycardia)</p>
          </list-item>
          <list-item>
            <p>Miosis</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal irritation</p>
          </list-item>
        </list>
        <p>
<bold>Toxicity</bold>
</p>
        <p>An overdose of phenoxybenzamine can result in blockade of the sympathetic nervous system and circulating epinephrine, leading to symptoms such as postural hypotension (especially upon standing), tachycardia, dizziness, fainting, lethargy, vomiting, and shock. According to the US Food and Drug Administration (FDA) drug label, case reports have associated long-term use of phenoxybenzamine with the development of carcinoma, indicating that prolonged therapy is not advised.</p>
      </sec>
      <sec id="article-145107.s15" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>
<bold>External Beam Radiation Therapy</bold>
</p>
        <p>External beam radiation therapy can be effective for controlling primary and metastatic disease across various sites. Data from smaller studies suggest that these treatments can provide symptom relief and help in disease debulking.<xref ref-type="bibr" rid="article-145107.r51">[51]</xref><xref ref-type="bibr" rid="article-145107.r50">[50]</xref></p>
        <p>
<bold>Systemic Chemotherapy</bold>
</p>
        <p>Systemic chemotherapy may be considered for patients with extensive metastatic or unresectable disease. Reported treatment regimens for metastatic pheochromocytoma have included combinations of cyclophosphamide, doxorubicin, dacarbazine, and vincristine.<xref ref-type="bibr" rid="article-145107.r57">[57]</xref><xref ref-type="bibr" rid="article-145107.r58">[58]</xref>&#x000a0;A&#x000a0;meta-analysis indicates that approximately 37% of patients respond to chemotherapy, although complete responses are rare.<xref ref-type="bibr" rid="article-145107.r59">[59]</xref><xref ref-type="bibr" rid="article-145107.r55">[55]</xref> Nonetheless, chemotherapy can reduce tumor size and improve blood pressure control.<xref ref-type="bibr" rid="article-145107.r57">[57]</xref><xref ref-type="bibr" rid="article-145107.r60">[60]</xref></p>
        <p>
<bold>Radionuclide Therapy</bold>
</p>
        <p><bold>MIBG:</bold> This treatment can only be considered for tumors&#x000a0;capable of taking up MIBG and is used in cases of unresectable disease or high tumor burden. Due to its structural similarity to norepinephrine, MIBG scintigraphy helps localize catecholamine-secreting tissues.<xref ref-type="bibr" rid="article-145107.r61">[61]</xref>&#x000a0;Treatment with iobenguane I-131 can lead to symptomatic relief in many patients and a reduction in tumor size in a considerable proportion of patients, which&#x000a0;is 24% to 45% of cases.<xref ref-type="bibr" rid="article-145107.r62">[62]</xref><xref ref-type="bibr" rid="article-145107.r63">[63]</xref><xref ref-type="bibr" rid="article-145107.r64">[64]</xref><xref ref-type="bibr" rid="article-145107.r65">[65]</xref></p>
        <p>
<bold>Novel Therapies</bold>
</p>
        <p>Recent advances in treating metastatic pheochromocytomas involve the use of agents that inhibit angiogenesis and proliferative signaling within tumor cells. These processes are driven by the interaction of growth factors, such as VEGF and platelet-derived growth factors (PDGF), with tyrosine kinase receptors, making them key therapeutic targets.<xref ref-type="bibr" rid="article-145107.r55">[55]</xref></p>
        <p><bold>Sunitinib:</bold> Sunitinib inhibits multiple receptors, including VEGF1, VEGF2, VEGF3, PDGF-&#x003b1;, PDGF-&#x003b2;, c-kit, fms-related tyrosine kinase 3, and the RET proto-oncogene, targeting angiogenesis and tumor cell proliferation.<xref ref-type="bibr" rid="article-145107.r55">[55]</xref><xref ref-type="bibr" rid="article-145107.r66">[66]</xref>&#x000a0;Sunitinib has been evaluated in small studies, with disease control rates&#x02014;comprising stable disease and partial responses&#x02014;ranging between 57% and 83%.<xref ref-type="bibr" rid="article-145107.r67">[67]</xref><xref ref-type="bibr" rid="article-145107.r68">[68]</xref> Median&#x000a0;progression-free survival has been reported between 4 and 13 months.<xref ref-type="bibr" rid="article-145107.r67">[67]</xref><xref ref-type="bibr" rid="article-145107.r68">[68]</xref>&#x000a0;As sunitinib can induce hypertension, antihypertensive therapy may require adjustment to maintain adequate blood pressure control during treatment.</p>
        <p><bold>Axitinib:</bold> This medication is an inhibitor of VEGF receptor 2 (VEGFR2), which is especially important in metastatic pheochromocytoma. These tumors often present a pseudohypoxic environment that stimulates VEGF synthesis, promoting angiogenesis.<xref ref-type="bibr" rid="article-145107.r55">[55]</xref> In phase 2 clinical trials, a partial response was observed in 36% of patients. Dosage adjustments are often necessary, as this medication can significantly worsen blood pressure control in a significant proportion of treated patients.<xref ref-type="bibr" rid="article-145107.r55">[55]</xref></p>
        <p>
<bold>Other Investigational Targeted Therapies</bold>
</p>
        <p>Investigational therapies include cabozantinib (a VEGFR2 and c-MET receptor inhibitor) and hypoxia-inducible factor 2&#x003b1; (HIF2A) inhibitors.</p>
      </sec>
      <sec id="article-145107.s16" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The risk of pheochromocytoma recurrence exists in both sporadic and familial cases. A study of 192 patients with pheochromocytomas and paragangliomas found that recurrence was more common in familial cases, as well as in right adrenal and extra-adrenal tumors.<xref ref-type="bibr" rid="article-145107.r69">[69]</xref>&#x000a0;</p>
        <p>A recent meta-analysis estimates that the recurrence rate after curative surgery is low, at approximately 3%, with a mean follow-up of 77 months.<xref ref-type="bibr" rid="article-145107.r70">[70]</xref>&#x000a0;The Endocrine Society Clinical Practice Guidelines recommend lifelong annual biochemical testing to monitor for recurrent or metastatic disease.<xref ref-type="bibr" rid="article-145107.r1">[1]</xref></p>
      </sec>
      <sec id="article-145107.s17" sec-type="Complications">
        <title>Complications</title>
        <p>Complications may include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Myocardial infarction</p>
          </list-item>
          <list-item>
            <p>Cardiogenic shock</p>
          </list-item>
          <list-item>
            <p>Cerebrovascular accident</p>
          </list-item>
          <list-item>
            <p>Renal failure</p>
          </list-item>
          <list-item>
            <p>Pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Acute respiratory distress syndrome</p>
          </list-item>
          <list-item>
            <p>Cardiac arrhythmias</p>
          </list-item>
          <list-item>
            <p>Lactic acidosis</p>
          </list-item>
          <list-item>
            <p>Hypertensive retinopathy</p>
          </list-item>
          <list-item>
            <p>Hypertensive encephalopathy</p>
          </list-item>
          <list-item>
            <p>Seizures (in children)</p>
          </list-item>
          <list-item>
            <p>Polydipsia (in children)</p>
          </list-item>
          <list-item>
            <p>Polyuria (in children)</p>
          </list-item>
          <list-item>
            <p>Cerebral vasculitis</p>
          </list-item>
          <list-item>
            <p>Ischemic enterocolitis</p>
          </list-item>
          <list-item>
            <p>Renal infarction</p>
          </list-item>
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145107.s18" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>The most common complication following tumor removal is hypotension, which may require fluid therapy and vasopressor support for several hours. However, advances in surgical and anesthetic techniques have reduced the risk of severe complications and mortality associated with the procedure in high-volume centers.</p>
      </sec>
      <sec id="article-145107.s19" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is essential in managing pheochromocytomas. Patients should understand the episodic nature of the symptoms associated with the condition and be informed that episodes of severe hypertension can be triggered by medications such as dopamine receptor antagonists, nonselective &#x003b2;-blockers, tricyclic antidepressants, corticosteroids, sympathomimetics, and neuromuscular agents. They should also be aware that such episodes may occur during surgery or anesthesia induction.</p>
        <p>Common episodic symptoms include headaches, sweating, heart racing, shortness of breath, chest pain, and anxiety.</p>
        <p>All patients diagnosed with pheochromocytoma, particularly those with a known family history of VHL syndrome, MEN2, or NF1, should be advised about the importance of genetic screening for their relatives. Several blood, urine, and imaging tests are available to aid in the diagnosis of pheochromocytoma. Treatment options include medications to manage blood pressure and other symptoms, as well as surgical removal of the tumor, which may be considered based on various factors.</p>
      </sec>
      <sec id="article-145107.s20" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Pheochromocytomas and Pregnancy</bold>
</p>
        <p>Pheochromocytomas present a rare yet anxiety-provoking condition in pregnant patients, with reported prevalence rates ranging from 1 in 15,000 to 1 in 54,000 pregnancies.<xref ref-type="bibr" rid="article-145107.r71">[71]</xref><xref ref-type="bibr" rid="article-145107.r72">[72]</xref>&#x000a0;The clinical course is often unpredictable, as increased catecholamine secretion into maternal circulation can lead to severe hypertension, uteroplacental ischemia, arrhythmias, and even death. Due to the rarity of this condition, there are currently no established guidelines for management in this setting.</p>
        <p>The authors provided valuable evidence to assist clinicians in a large international multicenter retrospective cohort study.<xref ref-type="bibr" rid="article-145107.r73">[73]</xref>&#x000a0;They&#x000a0;found that unrecognized and suboptimally treated pheochromocytoma and paraganglioma (PPGL) were associated with maternal or fetal death in 33 out of 230 pregnancies (14%). Patients with undiagnosed or untreated PPGLs faced a significantly increased risk of maternal and fetal complications, with an odds ratio of 27.0 (95% CI 3.5&#x02013;3473.1) compared to those with PPGLs identified before pregnancy. This highlights the importance of initiating adrenoceptor blockade following the diagnosis of the tumor.</p>
        <p>The authors reported that severe maternal complications occurred in 7% of pregnancies associated with untreated PPGL, with a mortality rate of 1%. Overall, fetal mortality was reported at 9%, a rate significantly lower than those found in previously published literature. Abdominal and pelvic PPGLs were associated with a higher incidence of adverse events, likely due to compression by the uterus or increased catecholamine release. Tumor size was not associated with a higher rate of complications at delivery, and the type of delivery did not correlate with adverse outcomes.</p>
        <p>Antepartum surgery did not show improved outcomes, with adverse events occurring in 8% of such pregnancies. If surgery is necessary, the second trimester is considered safer than the first. Metastatic PPGL was not associated with adverse outcomes, likely due to closer monitoring and treatment. Additionally, the authors reported lower adverse outcomes in syndromic PPGL, which was thought to be secondary to earlier diagnosis and treatment.</p>
        <p>In conclusion, undiagnosed and untreated PPGL was associated with a significantly higher risk of maternal and fetal complications compared to the excellent outcomes observed in patients treated with &#x003b1;-adrenergic blockade agents, such as phenoxybenzamine and doxazosin, during pregnancy. The transperitoneal approach is preferred for laparoscopic resection, as the prone positioning required for the extraperitoneal approach is contraindicated during pregnancy.<xref ref-type="bibr" rid="article-145107.r74">[74]</xref></p>
      </sec>
      <sec id="article-145107.s21" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with pheochromocytoma are at risk for numerous complications, making early identification and management essential for reducing morbidity and mortality. A collaborative approach among healthcare professionals is crucial to ensure patient-centered care and improve overall outcomes. Endocrinologists, endocrine surgeons, emergency medicine physicians, critical care physicians, advanced practitioners, nurses, pharmacists, and other healthcare providers involved in the care of these patients must possess the necessary clinical skills and knowledge for accurate diagnosis and management. This expertise includes recognizing the diverse clinical presentations and understanding the intricacies of diagnostic testing and laboratory interpretation.</p>
        <p>A strategic approach is equally essential, incorporating evidence-based strategies to optimize treatment plans and minimize adverse effects. Ethical considerations should guide decision-making, ensuring informed consent and respecting patient autonomy in treatment choices. Each healthcare professional must understand their responsibilities and contribute their unique expertise to the patient's care plan, thereby fostering a multidisciplinary approach. Effective interprofessional communication is vital, facilitating seamless information exchange and collaborative decision-making among healthcare team members.</p>
        <p>Care coordination is crucial in ensuring that the patient's journey from diagnosis to treatment and follow-up is effectively managed, minimizing errors and enhancing patient safety. By embracing principles of skill, strategy, ethics, responsibility, interprofessional communication, and care coordination, healthcare professionals can provide patient-centered care, ultimately improving outcomes and enhancing team performance in the management of pheochromocytomas.</p>
      </sec>
      <sec id="article-145107.s22">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145107&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145107">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/pheochromocytoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=145107">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/145107/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=145107">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-145107.s23">
        <fig id="article-145107.image.f1" position="float" orientation="portrait">
          <caption>
            <p>A Giant Pheochromocytoma. Contributed by S Munakomi, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="A__Giant__Pheochromocytoma2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-145107.s24">
        <fig id="article-145107.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Gross Specimen of a Giant Pheochromocytoma. Contributed by S Munakomi, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PHEO2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-145107.s25">
        <title>References</title>
        <ref id="article-145107.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gimenez-Roqueplo</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Grebe</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>99</volume>
            <issue>6</issue>
            <fpage>1915</fpage>
            <page-range>1915-42</page-range>
            <pub-id pub-id-type="pmid">24893135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>JWM</given-names>
              </name>
              <name>
                <surname>Kerstens</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Amar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prejbisz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robledo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taieb</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Crona</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zelinka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mannelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deutschbein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Timmers</surname>
                <given-names>HJLM</given-names>
              </name>
              <name>
                <surname>Castinetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dralle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Widimsk&#x000fd;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gimenez-Roqueplo</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension.</article-title>
            <source>J Hypertens</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>1443</fpage>
            <page-range>1443-1456</page-range>
            <pub-id pub-id-type="pmid">32412940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Chatellier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fofol</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Tumor recurrence and hypertension persistence after successful pheochromocytoma operation.</article-title>
            <source>Hypertension</source>
            <year>1997</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>1133</fpage>
            <page-range>1133-9</page-range>
            <pub-id pub-id-type="pmid">9149678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osinga</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Links</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Dullaart</surname>
                <given-names>RPF</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van der Horst-Schrivers</surname>
                <given-names>ANA</given-names>
              </name>
              <name>
                <surname>Kerstens</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Kema</surname>
                <given-names>IP</given-names>
              </name>
            </person-group>
            <article-title>Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.</article-title>
            <source>FASEB J</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>2226</fpage>
            <page-range>2226-2240</page-range>
            <pub-id pub-id-type="pmid">28264974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumann</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bayley</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Schiavi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Opocher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boedeker</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tirosh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castinetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beltsevich</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Groeben</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>von Dobschuetz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gimm</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wohllk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pfeifer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Louren&#x000e7;o</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Peczkowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patocs</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ngeow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Makay</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Tischler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leijon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pennelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Villar G&#x000f3;mez de Las Heras</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Links</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Bausch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>T201</fpage>
            <page-range>T201-T219</page-range>
            <pub-id pub-id-type="pmid">29794110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lo</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Wat</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Adrenal pheochromocytoma remains a frequently overlooked diagnosis.</article-title>
            <source>Am J Surg</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>179</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-5</page-range>
            <pub-id pub-id-type="pmid">10827323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ariton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Juan</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>AvRuskin</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital.</article-title>
            <source>Endocr Pract</source>
            <year>2000</year>
            <season>May-Jun</season>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-52</page-range>
            <pub-id pub-id-type="pmid">11421540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Biochemical Diagnosis of Pheochromocytoma and Paraganglioma</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Mariani-Costantini</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <source>Paraganglioma: A Multidisciplinary Approach [Internet]</source>
            <publisher-name>Codon Publications</publisher-name>
            <publisher-loc>Brisbane (AU)</publisher-loc>
            <year>2019</year>
            <month>07</month>
            <day>02</day>
            <pub-id pub-id-type="pmid">31294941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Preoperative management of the pheochromocytoma patient.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>92</volume>
            <issue>11</issue>
            <fpage>4069</fpage>
            <page-range>4069-79</page-range>
            <pub-id pub-id-type="pmid">17989126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <collab>AACE Adrenal Scientific Committee</collab>
            </person-group>
            <article-title>PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.</article-title>
            <source>Endocr Pract</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>690</fpage>
            <page-range>690-704</page-range>
            <pub-id pub-id-type="pmid">28332883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kaindl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>H&#x000fc;bner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sunahara</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Gmeiner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kobilka</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Binding pathway determines norepinephrine selectivity for the human &#x003b2;<sub>1</sub>AR over &#x003b2;<sub>2</sub>AR.</article-title>
            <source>Cell Res</source>
            <year>2021</year>
            <month>May</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>569</fpage>
            <page-range>569-579</page-range>
            <pub-id pub-id-type="pmid">33093660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perez</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>&#x003b1;<sub>1</sub>-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition.</article-title>
            <source>Front Pharmacol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>581098</fpage>
            <pub-id pub-id-type="pmid">33117176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundaresan</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Differential regulation of beta-adrenergic receptor-coupled adenylate cyclase by thyroid hormones in rat liver and heart: possible role of corticosteroids.</article-title>
            <source>Horm Res</source>
            <year>1987</year>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-18</page-range>
            <pub-id pub-id-type="pmid">2820855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motulsky</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Insel</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Adrenergic receptors in man: direct identification, physiologic regulation, and clinical alterations.</article-title>
            <source>N Engl J Med</source>
            <year>1982</year>
            <month>Jul</month>
            <day>01</day>
            <volume>307</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-29</page-range>
            <pub-id pub-id-type="pmid">6123082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciaraldi</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Marinetti</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>Hormone action at the membrane level. VIII. Adrenergic receptors in rat heart and adipocytes and their modulation by thyroxine.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>1978</year>
            <month>Jul</month>
            <day>03</day>
            <volume>541</volume>
            <issue>3</issue>
            <fpage>334</fpage>
            <page-range>334-46</page-range>
            <pub-id pub-id-type="pmid">149563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nazari</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rosenblum</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Haigney</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rosing</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2020</year>
            <month>Jul</month>
            <day>28</day>
            <volume>76</volume>
            <issue>4</issue>
            <fpage>451</fpage>
            <page-range>451-464</page-range>
            <pub-id pub-id-type="pmid">32703516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munakomi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajbanshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adhikary</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Case Report: A giant but silent adrenal pheochromocytoma - a rare entity.</article-title>
            <source>F1000Res</source>
            <year>2016</year>
            <volume>5</volume>
            <fpage>290</fpage>
            <pub-id pub-id-type="pmid">27785358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cajipe</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaushik</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Giant cystic pheochromocytoma.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>Nov</month>
            <day>08</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">29122903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lonser</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Libutti</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Linehan</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Oldfield</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>von Hippel-Lindau disease.</article-title>
            <source>Lancet</source>
            <year>2003</year>
            <month>Jun</month>
            <day>14</day>
            <volume>361</volume>
            <issue>9374</issue>
            <fpage>2059</fpage>
            <page-range>2059-67</page-range>
            <pub-id pub-id-type="pmid">12814730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zbar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Crossey</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Affara</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Ferguson-Smith</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Brauch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Glavac</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Tisherman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mulvihill</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shuin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Whaley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seizinger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olschwang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boisson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lips</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lerman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.</article-title>
            <source>Hum Mutat</source>
            <year>1996</year>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>348</fpage>
            <page-range>348-57</page-range>
            <pub-id pub-id-type="pmid">8956040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Bornstein</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Vortmeyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mannelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Linehan</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>May</month>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>1999</fpage>
            <page-range>1999-2008</page-range>
            <pub-id pub-id-type="pmid">11344198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frank-Raue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rondot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raue</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.</article-title>
            <source>Mol Cell Endocrinol</source>
            <year>2010</year>
            <month>Jun</month>
            <day>30</day>
            <volume>322</volume>
            <issue>1-2</issue>
            <fpage>2</fpage>
            <page-range>2-7</page-range>
            <pub-id pub-id-type="pmid">20083156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gutmann</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Ferner</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Listernick</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Korf</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Wolters</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Neurofibromatosis type 1.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Feb</month>
            <day>23</day>
            <volume>3</volume>
            <fpage>17004</fpage>
            <pub-id pub-id-type="pmid">28230061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeBella</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Szudek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children.</article-title>
            <source>Pediatrics</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>105</volume>
            <issue>3 Pt 1</issue>
            <fpage>608</fpage>
            <page-range>608-14</page-range>
            <pub-id pub-id-type="pmid">10699117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walther</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Herring</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Enquist</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Keiser</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Linehan</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>von Recklinghausen's disease and pheochromocytomas.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>162</volume>
            <issue>5</issue>
            <fpage>1582</fpage>
            <page-range>1582-6</page-range>
            <pub-id pub-id-type="pmid">10524872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Parenti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Subclinical phaeochromocytoma.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>507</fpage>
            <page-range>507-15</page-range>
            <pub-id pub-id-type="pmid">22863392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Timmers</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kozupa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raygada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Solis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>779</fpage>
            <page-range>779-86</page-range>
            <pub-id pub-id-type="pmid">17200167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsujimoto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manger</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Desensitization of beta-adrenergic receptors by pheochromocytoma.</article-title>
            <source>Endocrinology</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>114</volume>
            <issue>4</issue>
            <fpage>1272</fpage>
            <page-range>1272-8</page-range>
            <pub-id pub-id-type="pmid">6323140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Streeten</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma.</article-title>
            <source>Am J Hypertens</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>760</fpage>
            <page-range>760-9</page-range>
            <pub-id pub-id-type="pmid">8862222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Joe</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Westphalen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>FV</given-names>
              </name>
            </person-group>
            <article-title>Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma.</article-title>
            <source>Int Braz J Urol</source>
            <year>2011</year>
            <season>Jan-Feb</season>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-40;discussion 40-1</page-range>
            <pub-id pub-id-type="pmid">21385478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Perioperative hypertensive crisis in clinically silent pheochromocytomas: report of four cases.</article-title>
            <source>Chang Gung Med J</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-50</page-range>
            <pub-id pub-id-type="pmid">15804148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kloos</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Korobkin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Incidentally discovered adrenal masses.</article-title>
            <source>Endocr Rev</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>460</fpage>
            <page-range>460-84</page-range>
            <pub-id pub-id-type="pmid">8521790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glazer</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Weyman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sagel</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Levitt</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>McClennan</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Nonfunctioning adrenal masses: incidental discovery on computed tomography.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>1982</year>
            <month>Jul</month>
            <volume>139</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-5</page-range>
            <pub-id pub-id-type="pmid">6979870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mantero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Terzolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arnaldi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Osella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Masini</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al&#x000ec;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giovagnetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Opocher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Angeli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>637</fpage>
            <page-range>637-44</page-range>
            <pub-id pub-id-type="pmid">10690869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrugia</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Charalampopoulos</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma.</article-title>
            <source>Endocr Regul</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>191</fpage>
            <page-range>191-212</page-range>
            <pub-id pub-id-type="pmid">31517632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000fc;rfeld</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pamporaki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peitzsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rayes</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sabri</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rohm</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biemann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sandner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>T&#x000f6;njes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>False-positive results for pheochromocytoma associated with norepinephrine reuptake blockade.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>31</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">37955319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kline</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sadrzadeh</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Very high rate of false positive biochemical results when screening for pheochromocytoma in a large, undifferentiated population with variable indications for testing.</article-title>
            <source>Clin Biochem</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>77</volume>
            <fpage>26</fpage>
            <page-range>26-31</page-range>
            <pub-id pub-id-type="pmid">31978379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Willemsen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Timmers</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Sweep</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Is supine rest necessary before blood sampling for plasma metanephrines?</article-title>
            <source>Clin Chem</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>352</fpage>
            <page-range>352-4</page-range>
            <pub-id pub-id-type="pmid">17200132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Jong</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Post</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Muskiet</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Kema</surname>
                <given-names>IP</given-names>
              </name>
            </person-group>
            <article-title>Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>8</issue>
            <fpage>2841</fpage>
            <page-range>2841-9</page-range>
            <pub-id pub-id-type="pmid">19567530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deutschbein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jaeger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Broecker-Preuss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Petersenn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-60</page-range>
            <pub-id pub-id-type="pmid">20039892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumann</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Bausch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McWhinney</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Bender</surname>
                <given-names>BU</given-names>
              </name>
              <name>
                <surname>Gimm</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Franke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schipper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klisch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Altehoefer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zerres</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Januszewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Munk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Glaesker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Apel</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Treier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reineke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walz</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Hoang-Vu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brauckhoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein-Franke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maier-Woelfle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pe&#x000e7;zkowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szmigielski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <collab>Freiburg-Warsaw-Columbus Pheochromocytoma Study Group</collab>
            </person-group>
            <article-title>Germ-line mutations in nonsyndromic pheochromocytoma.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>May</month>
            <day>09</day>
            <volume>346</volume>
            <issue>19</issue>
            <fpage>1459</fpage>
            <page-range>1459-66</page-range>
            <pub-id pub-id-type="pmid">12000816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarkadi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saskoi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Butz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Patocs</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Jan</month>
            <day>27</day>
            <volume>23</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">35163370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Ramamoorthy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nilubol</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2024</year>
            <month>Sep</month>
            <day>21</day>
            <fpage>101954</fpage>
            <pub-id pub-id-type="pmid">39366823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Curley</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Gagel</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Hickey</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma.</article-title>
            <source>Surgery</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>120</volume>
            <issue>6</issue>
            <fpage>1064</fpage>
            <page-range>1064-70; discussion 1070-1</page-range>
            <pub-id pub-id-type="pmid">8957496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumann</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bender</surname>
                <given-names>BU</given-names>
              </name>
              <name>
                <surname>Elsner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Janetschek</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>84</volume>
            <issue>8</issue>
            <fpage>2608</fpage>
            <page-range>2608-10</page-range>
            <pub-id pub-id-type="pmid">10443647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumann</surname>
                <given-names>HPH</given-names>
              </name>
              <name>
                <surname>Tsoy</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bancos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Amodru</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Walz</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Tirosh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bandgar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petrov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yukina</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Roslyakova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Horst-Schrivers</surname>
                <given-names>ANA</given-names>
              </name>
              <name>
                <surname>Berends</surname>
                <given-names>AMA</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Castroneves</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rizzati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dvorakova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hasse-Lazar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kvachenyuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peczkowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Erenler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Recasens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wohllk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Corssmit</surname>
                <given-names>EPM</given-names>
              </name>
              <name>
                <surname>Shafigullina</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Calissendorff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grozinsky-Glasberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kunavisarut</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schalin-J&#x000e4;ntti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castinetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vlcek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Beltsevich</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Egorov</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Schiavi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Links</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Lechan</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bausch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <collab>International Bilateral-Pheochromocytoma-Registry Group</collab>
            </person-group>
            <article-title>Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy.</article-title>
            <source>JAMA Netw Open</source>
            <year>2019</year>
            <month>Aug</month>
            <day>02</day>
            <volume>2</volume>
            <issue>8</issue>
            <fpage>e198898</fpage>
            <pub-id pub-id-type="pmid">31397861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ulchaker</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Novick</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Successful outcomes in pheochromocytoma surgery in the modern era.</article-title>
            <source>J Urol</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>161</volume>
            <issue>3</issue>
            <fpage>764</fpage>
            <page-range>764-7</page-range>
            <pub-id pub-id-type="pmid">10022680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McBride</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Atwell</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Charboneau</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Wass</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Callstrom</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy.</article-title>
            <source>J Vasc Interv Radiol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>1263</fpage>
            <page-range>1263-70</page-range>
            <pub-id pub-id-type="pmid">21856504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Goldner</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bergsland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blaszkowsky</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Brock</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Fanta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Halfdanarson</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heaney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heslin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kandeel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kardan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kuvshinoff</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Lieu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pillarisetty</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Reidy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salgado</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shaheen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Soulen</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Strosberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sussman</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Trikalinos</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Uboha</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Vijayvergia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lynn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hochstetler</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2021</year>
            <month>Jul</month>
            <day>28</day>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>839</fpage>
            <page-range>839-868</page-range>
            <pub-id pub-id-type="pmid">34340212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishbein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bonner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torigian</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Nathanson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Pryma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cengel</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.</article-title>
            <source>Horm Metab Res</source>
            <year>2012</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>405</fpage>
            <page-range>405-10</page-range>
            <pub-id pub-id-type="pmid">22566196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bancos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Bible</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Laack</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Foote</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hallemeier</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma.</article-title>
            <source>Adv Radiat Oncol</source>
            <year>2018</year>
            <season>Jan-Mar</season>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-29</page-range>
            <pub-id pub-id-type="pmid">29556576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Uemura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mezaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuwano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ebe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Komeyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Usuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maekawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sasano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kamoi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Histopathological analysis of spontaneous large necrosis of adrenal pheochromocytoma manifested as acute attacks of alternating hypertension and hypotension: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2016</year>
            <month>Oct</month>
            <day>12</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>279</fpage>
            <pub-id pub-id-type="pmid">27729064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koizumi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saiki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mikura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hashizume</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kigawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iizaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Otsuka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Isobe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Norose</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohike</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagasaka</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Continuous Hemodiafiltration for Pheochromocytoma Crisis with a Positive Outcome.</article-title>
            <source>Intern Med</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>58</volume>
            <issue>21</issue>
            <fpage>3113</fpage>
            <page-range>3113-3119</page-range>
            <pub-id pub-id-type="pmid">31292390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kariyasu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Machida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nishina</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tambo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miyagawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rakue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sumitani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shibahara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Emergent transcatheter arterial embolization to control critical blood pressure fluctuation associated with hypercatecholaminemic crisis in a patient with an unruptured retroperitoneal paraganglioma.</article-title>
            <source>Radiol Case Rep</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>2065</fpage>
            <page-range>2065-2071</page-range>
            <pub-id pub-id-type="pmid">34158896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jimenez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>277</fpage>
            <pub-id pub-id-type="pmid">29892268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roman-Gonzalez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ayala-Ramirez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Waguespack</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Habra</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Perrier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.</article-title>
            <source>Ann Surg</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>268</volume>
            <issue>1</issue>
            <fpage>172</fpage>
            <page-range>172-178</page-range>
            <pub-id pub-id-type="pmid">28257320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayala-Ramirez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Habra</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Perrier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waguespack</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.</article-title>
            <source>Cancer</source>
            <year>2012</year>
            <month>Jun</month>
            <day>01</day>
            <volume>118</volume>
            <issue>11</issue>
            <fpage>2804</fpage>
            <page-range>2804-12</page-range>
            <pub-id pub-id-type="pmid">22006217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanabe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuiki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsumagari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ichihara</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma.</article-title>
            <source>Horm Cancer</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-10</page-range>
            <pub-id pub-id-type="pmid">23361939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niemeijer</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Alblas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van Hulsteijn</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Corssmit</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>642</fpage>
            <page-range>642-51</page-range>
            <pub-id pub-id-type="pmid">25041164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Averbuch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fojo</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Oct</month>
            <day>15</day>
            <volume>113</volume>
            <issue>8</issue>
            <fpage>2020</fpage>
            <page-range>2020-8</page-range>
            <pub-id pub-id-type="pmid">18780317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Harst</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Bruining</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bonjer</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>de Krijger</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Lamberts</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>van de Meiracker</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Boomsma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stijnen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Bosman</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>86</volume>
            <issue>2</issue>
            <fpage>685</fpage>
            <page-range>685-93</page-range>
            <pub-id pub-id-type="pmid">11158032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loh</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.</article-title>
            <source>J Endocrinol Invest</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>648</fpage>
            <page-range>648-58</page-range>
            <pub-id pub-id-type="pmid">9492103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukherjee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Plowman</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hikmat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Britton</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Monson</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Besser</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-60</page-range>
            <pub-id pub-id-type="pmid">11453952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Troncone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rufini</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Nuclear medicine therapy of pheochromocytoma and paraganglioma.</article-title>
            <source>Q J Nucl Med</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>344</fpage>
            <page-range>344-55</page-range>
            <pub-id pub-id-type="pmid">10731785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sisson</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Radiopharmaceutical treatment of pheochromocytomas.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>970</volume>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">12381541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sadek</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Sunitinib: the antiangiogenic effects and beyond.</article-title>
            <source>Onco Targets Ther</source>
            <year>2016</year>
            <volume>9</volume>
            <fpage>5495</fpage>
            <page-range>5495-505</page-range>
            <pub-id pub-id-type="pmid">27660467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Kane</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ezzat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joshua</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bourdeau</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Leibowitz-Amit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Olney</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Krzyzanowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reuther</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Asa</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.</article-title>
            <source>Br J Cancer</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>120</volume>
            <issue>12</issue>
            <fpage>1113</fpage>
            <page-range>1113-1119</page-range>
            <pub-id pub-id-type="pmid">31105270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayala-Ramirez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chougnet</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Habra</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Leboulleux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cabanillas</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Caramella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Al Ghuzlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waguespack</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Deandreis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baudin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>97</volume>
            <issue>11</issue>
            <fpage>4040</fpage>
            <page-range>4040-50</page-range>
            <pub-id pub-id-type="pmid">22965939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Servais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gimenez-Roqueplo</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Zinzindohoue</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chatellier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Plouin</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>2110</fpage>
            <page-range>2110-6</page-range>
            <pub-id pub-id-type="pmid">15644401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holscher</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dreijerink</surname>
                <given-names>KMA</given-names>
              </name>
              <name>
                <surname>Engelsman</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Nieveen van Dijkum</surname>
                <given-names>EJM</given-names>
              </name>
            </person-group>
            <article-title>Recurrence Rate of Sporadic Pheochromocytomas After Curative Adrenalectomy: A Systematic Review and Meta-analysis.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2021</year>
            <month>Jan</month>
            <day>23</day>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>588</fpage>
            <page-range>588-597</page-range>
            <pub-id pub-id-type="pmid">33125073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrington</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Farley</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>van Heerden</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ramin</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Adrenal tumors and pregnancy.</article-title>
            <source>World J Surg</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>182</fpage>
            <page-range>182-6</page-range>
            <pub-id pub-id-type="pmid">9880429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenders</surname>
                <given-names>JWM</given-names>
              </name>
              <name>
                <surname>Langton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Langenhuijsen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Eisenhofer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma and Pregnancy.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>605</fpage>
            <page-range>605-617</page-range>
            <pub-id pub-id-type="pmid">31345526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bancos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>HPH</given-names>
              </name>
              <collab>International Pheochromocytoma and Pregnancy Study Group</collab>
            </person-group>
            <article-title>Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-21</page-range>
            <pub-id pub-id-type="pmid">33248478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145107.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Weerd</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Noord</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loeve</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knapen</surname>
                <given-names>MFCM</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Franssen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van der Marel</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Feelders</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>ENDOCRINOLOGY IN PREGNANCY: Pheochromocytoma in pregnancy: case series and review of literature.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>177</volume>
            <issue>2</issue>
            <fpage>R49</fpage>
            <page-range>R49-R58</page-range>
            <pub-id pub-id-type="pmid">28381449</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
